Market closed
Oragenics Inc./$OGEN
Oragenics shares are trading higher after the company received approval to start a Phase II trial for its concussion drug in Australia.
4 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.
Ticker
$OGEN
Sector
Trading on
AMEX
Industry
Biotechnology
Headquarters
Employees
4
ISIN
US6840235005
Website
Oragenics Inc. Metrics
BasicAdvanced
$3.9M
-
-$1.00
-
-
Price and volume
Market cap
$3.9M
52-week high
$0.31
52-week low
$0.16
Average daily volume
335K
Financial strength
Current ratio
1.037
Quick ratio
0.917
Total debt to equity
1,855.198
Interest coverage (TTM)
-45.63%
Management effectiveness
Return on assets (TTM)
-170.96%
Return on equity (TTM)
-748.05%
Valuation
Price to book
28.08
Price to tangible book (TTM)
28.08
Price to free cash flow (TTM)
-0.243
Growth
Earnings per share change (TTM)
-87.03%
3-year earnings per share growth (CAGR)
-48.83%
Oragenics Inc. News
AllArticlesVideos
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia
GlobeNewsWire·14 hours ago
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision
GlobeNewsWire·2 days ago
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Oragenics Inc. stock?
Oragenics Inc. (OGEN) has a market cap of $3.9M as of May 14, 2025.
What is the P/E ratio for Oragenics Inc. stock?
The price to earnings (P/E) ratio for Oragenics Inc. (OGEN) stock is 0 as of May 14, 2025.
Does Oragenics Inc. stock pay dividends?
No, Oragenics Inc. (OGEN) stock does not pay dividends to its shareholders as of May 14, 2025.
When is the next Oragenics Inc. dividend payment date?
Oragenics Inc. (OGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Oragenics Inc.?
Oragenics Inc. (OGEN) does not currently have a Beta indicator.